“Toxicity of ixekizumab was evaluated in vitro and in vivo in Cynomolgyus monkeys; studies were justified in Cynomolgus monkeys on the basis that other species did not show pharmacological sensitivity to ixekizumab whereas this was similar between humans and Cynomolgus monkeys.”
Binds human and cynomolgus IL-17A with similar affinity; lower rabbit binding; no binding to mouse or rat IL-17A
“The results demonstrate that ixekizumab binds human and cynomolgus monkey IL-17 with similar affinities in a concentration dependent manner. Ixekizumab also binds to rabbit IL-17, but the affinity is lower and heterogenous. However, ixekizumab shows no binding to both mouse and rat IL-17.”
✓ VerifiedFDA pharmacology/toxicology review, p. 15Source ↗
Surrogate molecule
No surrogate; the clinical antibody was tested in cynomolgus monkey (rat anti-mouse IL-17 antibodies used only in pharmacology models)
“Two surrogate antibodies that cross react with murine IL-17 were used in nonclinical collagen-induced arthritis (CIA) and experimental autoimmune encephalomyelitis (EAE) models.”
✓ VerifiedFDA pharmacology/toxicology review, p. 16Source ↗